162 related articles for article (PubMed ID: 22320249)
1. Novel method to measure serum levels of des-gamma-carboxy prothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report.
Toyoda H; Kumada T; Osaki Y; Tada T; Kaneoka Y; Maeda A
Cancer Sci; 2012 May; 103(5):921-5. PubMed ID: 22320249
[TBL] [Abstract][Full Text] [Related]
2. Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma.
Tameda M; Shiraki K; Sugimoto K; Ogura S; Inagaki Y; Yamamoto N; Ikejiri M; Takei Y; Ito M; Nobori T
Cancer Sci; 2013 Jun; 104(6):725-31. PubMed ID: 23480217
[TBL] [Abstract][Full Text] [Related]
3. Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma.
Tanaka T; Taniguchi T; Sannomiya K; Takenaka H; Tomonari T; Okamoto K; Kitamura S; Okahisa T; Tamaki K; Mikasa H; Suzuki S; Takayama T
J Gastroenterol Hepatol; 2013 Aug; 28(8):1348-55. PubMed ID: 23432345
[TBL] [Abstract][Full Text] [Related]
4. Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin.
Kurokawa T; Yamazaki S; Mitsuka Y; Moriguchi M; Sugitani M; Takayama T
Br J Cancer; 2016 Jan; 114(1):53-8. PubMed ID: 26679378
[TBL] [Abstract][Full Text] [Related]
5. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
6. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
7. The serum level of NX-DCP-R, but not DCP, is not increased in alcoholic liver disease without hepatocellular carcinoma.
Saito M; Yano Y; Hirano H; Momose K; Mouri K; Hishimoto A; Yoshida M; Azuma T
Cancer Biomark; 2016; 16(1):171-80. PubMed ID: 26600398
[TBL] [Abstract][Full Text] [Related]
8. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma.
Mita Y; Aoyagi Y; Yanagi M; Suda T; Suzuki Y; Asakura H
Cancer; 1998 May; 82(9):1643-8. PubMed ID: 9576283
[TBL] [Abstract][Full Text] [Related]
9. Increase of serum des-gamma-carboxy prothrombin in alcoholic liver disease without hepatocellular carcinoma.
Ohhira M; Ohtake T; Saito H; Ikuta K; Tanaka K; Tanabe H; Kawashima T; Fujimoto Y; Naraki T; Ono M; Kohgo Y
Alcohol Clin Exp Res; 1999 Apr; 23(4 Suppl):67S-70S. PubMed ID: 10235282
[TBL] [Abstract][Full Text] [Related]
10. Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma.
Sumi A; Akiba J; Ogasawara S; Nakayama M; Nomura Y; Yasumoto M; Sanada S; Nakashima O; Abe T; Yano H
PLoS One; 2015; 10(3):e0118452. PubMed ID: 25739032
[TBL] [Abstract][Full Text] [Related]
11. Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma.
Takeji S; Hirooka M; Koizumi Y; Tokumoto Y; Abe M; Ikeda Y; Nadano S; Hiasa Y; Onji M
J Gastroenterol Hepatol; 2013 Apr; 28(4):671-7. PubMed ID: 23215762
[TBL] [Abstract][Full Text] [Related]
12. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
14. Serum monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma.
Kiyokawa H; Yasuda H; Oikawa R; Okuse C; Matsumoto N; Ikeda H; Watanabe T; Yamamoto H; Itoh F; Otsubo T; Yoshimura T; Yoshida E; Nakagawa M; Koshikawa N; Seiki M
Cancer Sci; 2017 Jul; 108(7):1432-1439. PubMed ID: 28418226
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma.
Sassa T; Kumada T; Nakano S; Uematsu T
Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
Song P; Feng X; Inagaki Y; Song T; Zhang K; Wang Z; Zheng S; Ma K; Li Q; Kong D; Wu Q; Zhang T; Zhao X; Hasegawa K; Sugawara Y; Kokudo N; Tang W;
Biosci Trends; 2014 Oct; 8(5):266-73. PubMed ID: 25382443
[TBL] [Abstract][Full Text] [Related]
17. Plasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma.
Fujiyama S; Morishita T; Hashiguchi O; Sato T
Cancer; 1988 Apr; 61(8):1621-8. PubMed ID: 2450634
[TBL] [Abstract][Full Text] [Related]
18. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.
Hamamura K; Shiratori Y; Shiina S; Imamura M; Obi S; Sato S; Yoshida H; Omata M
Cancer; 2000 Apr; 88(7):1557-64. PubMed ID: 10738213
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
